Research Analysts’ Weekly Ratings Updates for Tvardi Therapeutics (TVRD)

A number of firms have modified their ratings and price targets on shares of Tvardi Therapeutics (NASDAQ: TVRD) recently:

• 7/8/2026 – Tvardi Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Tvardi Therapeutics was upgraded by UBS Group AG to “outperform”. They now have a $10.00 price target on the stock.
• 7/8/2026 – Tvardi Therapeutics was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $13.00 price target on the stock.
• 7/8/2026 – Tvardi Therapeutics was upgraded by Raymond James Financial, Inc. from “market perform” to “outperform”. They now have a $10.00 price target on the stock.
• 7/7/2026 – Tvardi Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.
• 6/8/2026 – Tvardi Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $9.00 price target on the stock.

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.